✨ Free AI Report
Amarin Corporation plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Amarin Corporation plc
Company Research

Amarin Corporation plc: Business Overview, Financials & Competitive Analysis

Amarin Corporation plc scores 6/10 on the AskCyborg Cyborg Score (Solid). Specialty cardiovascular pharmaceutical company with established commercial infrastructure and international expansion opportunities offsetting single-product concentration risk. Amarin is an established commercial-stage pharmaceutical company with a FDA-approved flagship product (VASCEPA) generating revenue. The narrow focus on cardiovascular therapeutics and reliance on a single product present concentration risk, but successful commercialization.

What is Amarin Corporation plc's industry? Amarin Corporation plc (amarincorp.com) operates in Cardiovascular Drugs. AskCyborg classifies Amarin Corporation plc under Cardiovascular Drugs in its company registry.

Amarin Corporation plc is a pharmaceutical company that engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. ...

6/ 10Solid

Cyborg Score thesis

Specialty cardiovascular pharmaceutical company with established commercial infrastructure and international expansion...

Read the full analyst-debate transcript →
Industry Cardiovascular Drugs
4 named competitors
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Amarin Corporation plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Amarin Corporation plc

AskCyborg analysts argue the bull and bear cases for Amarin Corporation plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Amarin Corporation plc OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Amarin Corporation plc Overview

Pro stress-test →

Amarin Corporation plc is a pharmaceutical company that engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Strategic Profile

Pro stress-test →

The company sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. Amarin has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA.

Competitive Landscape

Pro stress-test →

Amarin competes in the specialty cardiovascular pharmaceutical space against established players offering alternative triglyceride-lowering agents and lipid management therapies. Key competitors include major pharmaceutical companies with broader cardiovascular portfolios and other omega-3 or prescription lipid-focused manufacturers.

Industry Context

Amarin Corporation plc operates in Cardiovascular Drugs.

Key facts

Founded: 1989 · Headquarters: Dublin, Ireland · Employees: 501–1000 · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Amarin Corporation plc.

  • VASCEPA is the company's core revenue driver; commercial success depends on prescription volume growth and market penetration in cardiovascular disease management
  • International expansion underway in Canada, Lebanon, and UAE; regulatory approvals sought in China, Europe, and other Middle Eastern markets
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RepathaPrescription PCSK9 inhibitor for cardiovascular disease and lipid management→PraluentPCSK9 inhibitor for lowering LDL cholesterol in cardiovascular patients→NexletolBempedoic acid for lowering LDL cholesterol and triglycerides→InclisiranPCSK9 inhibitor for cardiovascular disease and lipid management→

Compare Amarin Corporation plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Amarin Corporation plc operates in Cardiovascular Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Cardiovascular Drugs research →
NEW · MCP server

Ask your AI assistant about Amarin Corporation plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Amarin Corporation plc and its top competitor on Cyborg Score”
“What did Amarin Corporation plc do this quarter?”
“Is Amarin Corporation plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Amarin Corporation plc do?+
Amarin Corporation plc is a pharmaceutical company that engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. ...
What is Amarin Corporation plc's Cyborg Score?+
Amarin Corporation plc has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Amarin Corporation plc's main competitors?+
Named competitors include Repatha, Praluent, Nexletol, Inclisiran. The full competitive landscape is in the AskCyborg report.
How can I get the full Amarin Corporation plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Amarin Corporation plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Amarin Corporation plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.